2024年，公司拟中选品种的销售情况如下： 1 产品名称 适应症 规格 拟 中 选 价 格（元/瓶） 拟主供省份 注射用头 孢唑肟钠 注射用头孢唑肟钠属于第三代头孢菌素类抗生 素，具有广谱抗菌作用，适用于敏感菌所致的下 呼吸道感染、尿路感染、腹腔感染、盆腔感染、 败血症、皮肤软组织感染、骨和关节感染、肺炎 链球菌或流感嗜血杆菌所致脑膜炎和单纯性淋 病。 1.0g 3.65 福建、重庆、 江西 一、拟中选产品的基本情况 证券代码：002370 证券简称：亚太药业 公告编号：2025-089 浙江亚太药业股份有限公司 关于公司参与全国药品集中采购拟中选的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，不 存在虚假记载、误导性陈述或者重大遗漏。 浙江亚太药业股份有限公司（以下简称"亚太药业"或"公司"） 于近日参加了国家组织药品联合采购办公室（以下简称"联采办"） 组织开展的第十一批全国药品集中采购的投标工作，公司产品注射用 头孢唑肟钠拟中选本次集中采购，现将相关情况公告如下： 注：1、上述产品的拟中选价格等信息以联采办发布的最终结果为准。 2、根据相关规定，本次拟中选产品的采购周期自中选结果执行之日起至 ...

杭州市上城区新业路 8 号华联时代大厦 B 幢 22 层 电话：0571-88362156 传真：0571-88362156 邮编：310016 北京国枫（杭州）律师事务所 关于浙江亚太药业股份有限公司 2025 年第二次临时股东大会的 法律意见书 国枫律股字[2025]G0019 号 致：浙江亚太药业股份有限公司（贵公司） 北京国枫（杭州）律师事务所（以下称"本所"）接受贵公司的委托，指派律师出席 并见证贵公司2025年第二次临时股东大会（以下称"本次会议"）。 本所律师根据《中华人民共和国公司法》（以下称《公司法》）《中华人民共和国证 券法》（以下称《证券法》）《上市公司股东会规则》（以下称《股东会规则》）《律师事务 所从事证券法律业务管理办法》（以下称《证券法律业务管理办法》）及《律师事务所证 券法律业务执业规则（试行）》（以下称《证券法律业务执业规则》）等相关法律、行政 法规、规章、规范性文件及《浙江亚太药业股份有限公司章程》（以下称《公司章程》） 的规定，就本次会议的召集与召开程序、召集人资格、出席会议人员资格、会议表决程 序及表决结果等事宜，出具本法律意见书。 对本法律意见书的出具，本所律师特作如 ...

证券代码：002370 证券简称：亚太药业 公告编号：2025-088 浙江亚太药业股份有限公司 2025 年第二次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 特别提示 1、本次股东大会未出现否决议案的情形； 2、本次股东大会未涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 （一）会议召开情况 1、会议召开时间 现场会议召开时间：2025 年 10 月 29 日下午 14：00 网络投票时间： 其中：通过深圳证券交易所交易系统进行网络投票的具体时间为 2025年 10月29日上午9:15—9:25，9:30－11:30，下午13:00－15:00； 通 过 深 圳 证 券 交 易 所 互 联 网 投 票 系 统 （http://wltp.cninfo.com.cn）投票的具体时间为 2025 年 10 月 29 日上午 9：15 至下午 15：00 的任意时间。 2、现场会议召开地点：浙江省绍兴滨海新城沥海镇南滨西路 36 号公司办公楼三楼会议室 3、会议召集人：浙江亚太药业股份有限公司董事会。 4、会议召开方式：本次会议 ...

New Stock Issuance - Multiple companies are experiencing significant abnormal fluctuations in stock prices, including 香农芯创 (300475) with a notice date of 2025-10-24[1] - 天普股份 (605255) reported on 2025-10-21[1] - 生益电子 (688183) and 达华智能 (002512) both reported on 2025-10-29[1] Trading Alerts - 21 companies have been flagged for abnormal trading activities as of 2025-10-29, indicating potential volatility in the market[1] - ST新华锦 (600735) and 汇绿生态 (001267) are among those with recent alerts on 2025-10-29[1] - The report includes links to detailed announcements for each company, providing transparency and further information for investors[1] Market Trends - The report highlights a trend of increased scrutiny on companies with abnormal stock price movements, suggesting a potential shift in regulatory focus[1] - Investors are advised to monitor these stocks closely due to the heightened risk associated with abnormal fluctuations[1]

Core Viewpoint - Zhejiang Apac Pharmaceutical Co., Ltd. has reported significant growth in its third-quarter results, with a net profit increase of 2,909.49% year-on-year, indicating a strong operational performance and market expectations being met [1][2]. Financial Performance - For the first three quarters, the company achieved a revenue of 228,305,775.20 yuan and a net profit attributable to shareholders of 97,195,012.22 yuan [1]. - The third quarter alone saw revenues of 76,231,043.79 yuan, with a 47.69% increase in net profit after excluding non-recurring gains and losses [1]. - The net assets of the company reached 1.121 billion yuan, reflecting a 15.33% growth compared to the end of the previous year [2]. - Cash reserves exceeded 610 million yuan, indicating strong liquidity and financial resilience [2]. - The company has eliminated short-term borrowings and non-current liabilities due within one year, showcasing excellent short-term debt repayment capability [2]. Strategic Developments - The company announced a change in actual control, with Qiu Zhongxun, the chairman of Yaodou Technology, set to become the new controlling shareholder [1]. - A directed issuance of 700 million yuan will be made to the new controlling shareholder, with all funds allocated for new drug research and development, reflecting confidence in the company's transformation towards innovative drugs [1][4]. - The strategic focus on innovative drug development aligns with national policies supporting high-tech industries, positioning the company to capitalize on significant market opportunities [3][4]. Industry Context - The "14th Five-Year Plan" emphasizes the growth of high-tech industries, particularly in innovative pharmaceuticals, which are expected to benefit from strong policy support [3]. - The innovative drug sector is projected to experience rapid growth, with the number of clinical trial applications (INDs) reaching 428, a 35% increase year-on-year, and the total value of domestic innovative drug licensing transactions exceeding 20 billion USD [3]. Innovation and R&D Focus - The company plans to invest in oncolytic virus drug development and long-acting formulations, targeting multiple innovative drug pipelines [4]. - The market for related anti-tumor biological drugs is expected to reach approximately 160 billion yuan in China and the U.S. by 2025, indicating a promising market outlook [4]. Synergy and Business Model - The integration of traditional pharmaceutical operations with innovative drug development is seen as a complementary relationship, where stable cash flow from traditional products supports high investment in R&D [6]. - The company holds 114 approved drug formulations, with over half being antibiotics, providing a solid cash flow foundation for future innovations [6]. - The new controlling shareholder's resources and the existing antibiotic business are expected to create synergies that enhance commercialization capabilities [6][7]. Market Positioning - The company is leveraging Yaodou Technology's extensive digital marketing network to enhance the distribution of its antibiotic products, particularly in grassroots medical institutions [7]. - This strategic positioning allows the company to respond effectively to market demand fluctuations, especially during peak seasons for respiratory diseases [7]. - The dual focus on maintaining traditional business stability while advancing into innovative drug development is viewed as a healthy transition strategy for the company [7].

Group 1 - The core point of the article is that Asia-Pacific Pharmaceutical reported a significant decline in revenue for the first three quarters of 2025, while net profit saw an extraordinary increase compared to the previous year [2] Group 2 - For the first three quarters of 2025, the company achieved a revenue of 228,305,775.20 yuan, representing a year-on-year decrease of 25.59% [2] - The net profit attributable to shareholders of the listed company was 97,195,012.22 yuan, showing a remarkable year-on-year growth of 2909.49% [2]

Core Insights - The company reported a revenue of 228 million yuan for the first three quarters of 2025, representing a year-on-year decline of 25.59% [1] - The net profit attributable to shareholders reached 97.195 million yuan, showing a significant year-on-year increase of 2909.49% [1] - The net loss attributable to shareholders, after excluding non-recurring gains and losses, amounted to 56.5853 million yuan [1] Financial Performance - Revenue for the first three quarters: 228 million yuan, down 25.59% year-on-year [1] - Net profit attributable to shareholders: 97.195 million yuan, up 2909.49% year-on-year [1] - Net loss attributable to shareholders (excluding non-recurring items): 56.5853 million yuan [1]

Core Viewpoint - Asia-Pacific Pharmaceutical (002370) reported a significant increase in net profit due to the sale of a subsidiary, despite a decline in revenue [1] Financial Performance - The company achieved an operating revenue of 228 million yuan in the first three quarters, a year-on-year decrease of 25.59% [1] - The net profit attributable to shareholders reached 97.195 million yuan, marking a year-on-year increase of 2909.49% [1] - The non-recurring net profit was -56.5853 million yuan, reflecting a year-on-year decline of 150.47% [1] Key Events - The substantial increase in net profit was primarily attributed to the sale of 100% equity in its wholly-owned subsidiary, Shaoxing Xingya Pharmaceutical Co., Ltd., which contributed approximately 149 million yuan to the total profit [1]

Group 1 - Company reported Q3 performance with revenue of approximately 228 million yuan, a year-on-year decrease of 25.59% [1] - Net profit attributable to shareholders was approximately 97.2 million yuan, a year-on-year increase of 2909.49% [1] - Basic earnings per share increased to 0.1313 yuan, a year-on-year increase of 2444.64% [1] Group 2 - As of the report, the market capitalization of the company is 5.3 billion yuan [2]

亚太药业公告，第三季度营收为7623.1万元，下降10.21%；净利润亏损798.15万元。前三季度营收为 2.28亿元，下降25.59%；净利润为9719.5万元，增长2,909.49%。 ...